by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : October 2009
Volume 19 • Number 3 • October 2009 Australasian BioTechnology 17 AusBioFEATURE --- AusBiotech 2009 Canada – a Leader in Life Sciences Snapshot of Canada’s Biopharma Industry Canada is home to the third largest biopharma • industry in the world, with a research community of over 100 institutes and 30,000 scientists. US$20 billion domestic pharmaceutical market (eighth • largest worldwide) in 2007. US$4.2 billion in biopharma industry revenues (2007). • US$1 billion in capital attracted (2007). • Canadian drug prices were the second highest of the • G7, behind the US, making Canada the second most profitable pharmaceutical market on a percentage basis. R&D spend by pharmaceutical industry in 2007 was • US$1.5 billion; biotechnology R&D spend was US$1.7 billion. Second among OECD countries in tax relief per R&D • dollar spend. Canada has the highest rate of increase in the G7 in • life sciences R&D workers, external patent applications and business expenditures on R&D. Most major pharmaceutical companies have • manufacturing and R&D facilities in Canada-- including small molecule and biologics facilities from pilot to commercial scale. Canadian drug regulations and review procedures are • on par with major regulated markets (US, EU) and its regulatory agency has a mutual recognition agreement with EU & Australian drug regulators. The Canadian life sciences community is keenly aware of the need to form global partnerships in order to fully leverage financial resources and intellectual capital. Many have already joined forces with Australian and other Asia Pacific partners to co-develop and commercialise technology. Partnering success stories and Canada’s progress in biomarker research, development and commerciali- sation will be showcased at the AusBiotech 2009 con- ference, on the afternoon of Wednesday 28 October. Reasons to conduct your trials in Canada Clinical investigator and research-associated costs are • generally lower in Canada than the US. Efficiencies in regulatory and ethics review and patient • recruitment enable faster completion of trials in Canada than in other OECD countries. Canadian clinical and analytical data can be used for • US or EU drug submissions. Health Canada speeds up the drug approval process • with Clinical Trial Applications reviewed in 30 days, and 7 days to review Phase 1 equivalency trial applications. New drug applications take 300 days for standard • new drug submissions and 180 days for priority review submissions. Health Canada is a member of the international • committee on regulatory harmonization (ICH) and has common review requirements with the FDA and EMEA. Canadian contract service providers can help you • benefit from the C$3 billion Scientific Research and Experimental Development (SRED) Program Tax assistance, and the Canadian Export Development Corporation can accelerate tax refunds through bridge financing. Contact: Ms Kishani Navaratnam, Trade Commissioner Consulate General of Canada in Sydney email@example.com Tel: 61 2 9364 3049; Mob: 61 414 183 985 Canada’s Life Sciences Community 23% Québec 32% Ontario 27% Western Canada (AB, BC) 8% Prairies (SK, MB) 10% Atlantic (NB, NL, NS, PE) Other global biopharma Therapeutics 166 Industrial and Environmental 115 AgroBio (including food and nutraceuticals) 88 Other research and manufacturing services 60 Bioinformatics, Analytical, Genomics and Proteomics 105 22 Product Pipeline for Canadian Health Biotech Companies Discovery & Preclinical 0 50 100 150 142 Phase I 77 Phase II 71 34 Phase III Biotechnology Products in Canadian Company Pipelines (by phase) It may be common knowledge that Canada has a significant life sciences industry. But, some facts may surprise you...